Israeli Pharma gets FDA Approval for Asthma Antibody
Help eligible, commercially insured patients save on out-of-pocket costs for CINQAIR*
TA479 Review decision paper
Australian Public Assessment Report Reslizumab
Llega reslizumab, terapia adicional reduce exacerbaciones asma grave
Cinqair (reslizumab)- Asthma- by Saro Arakelians, PharmD- Episode # 123 - YouTube
CINQAIR® (reslizumab) Injection – About Asthma Control
Brand name: Auvi-Q
Teva files MAA for asthma treatment reslizumab
Cinqair (reslizumab) Injection for treatment of Severe Asthma and an Eosinophilic Phenotype - Clinical Trials Arena
Teva Reports Two Successful Phase III Studies For Reslizumab In Asthma
NICE Recommends CINQAERO (reslizumab) for the Treatment of Severe Eosinophilic Asthma » FINCHANNEL
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials - The Lancet Respiratory Medicine
A program supporting CINQAIR® (reslizumab) Injection patients
Predicting Responders to Reslizumab after 16 Weeks of Treatment Using an Algorithm Derived from Clinical Studies of Patients wit
Rx Item-Cinqair (Reslizumab) 10Mg/Ml Inj Sinle Use Vial 10Ml By Teva Respiratory
Teva-Handok wins approval for anti-asthma injection < Pharma < Article - KBR
FDA approves Teva's Cinqair (reslizumab) Injection
Dosing and Administration
These highlights do not include all the information needed to use CINQAIR safely and effectively. See full prescribing information for CINQAIR.CINQAIR® (reslizumab) injection, for intravenous useInitial U.S. Approval: 2016
Medication Detail
Reslizumab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
Teva's severe eosinophilic asthma drug Cinqaero wins EU approval
Reslizumab | Teva UK
